Gemcitabine News and Research

RSS

Gemcitabine is the active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used together with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite

Positive clinical data from Phase II study of elacytarabine in patients with AML reported

Clavis Pharma ASA announces that positive clinical data from its Phase II study with its lead cancer product candidate elacytarabine in patients with late-stage acute myeloid leukaemia (AML) was presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, LA, USA.

7 Dec 2009

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

Allos Therapeutics, Inc. today reported new analyses of data from the Company’s pivotal PROPEL trial of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

7 Dec 2009

Data from brentuximab vedotin and dacetuzumab programs to be presented by Seattle Genetics

Seattle Genetics, Inc. today announced that data from its brentuximab vedotin (SGN-35) and dacetuzumab (SGN-40) programs will be reported at the upcoming 51st American Society of Hematology (ASH) 2009 Meeting and Exposition being held December 5-8, 2009 in New Orleans, Louisiana.

2 Dec 2009

Cromoz's new drug delivery system to reduce amount of drugs used in cancer treatment

Cromoz Inc., located in Research Triangle Park, will initiate water-soluble carbon nanotube-based cancer drug delivery system in Hyderabad, India. The water-soluble carbon nanotubes, which have functional groups on the walls that allows for conjugation with cancer drugs, was developed in partnership with the Indian Institute of Kanpur (ITT). The conjugated carbon nanotubes serves as a drug delivery vehicle with the ability to target the cancer site which has the potential to increase the drug efficacy.

28 Nov 2009

Clavis Pharma signs drug development and commercialisation agreement with Clovis Oncology

Clavis Pharma ASA, the clinical stage oncology focused pharmaceutical company, and Clovis Oncology, Inc., the newly formed oncology company led by former Pharmion Corporation executives, announced today an agreement for the further development and commercialisation of the Clavis Pharma drug candidate, CP-4126, currently in Phase II development in pancreatic cancer.

24 Nov 2009

Press conference highlights emerging treatments in pancreatic cancer

As part of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Thompson will moderate a press conference on emerging treatments in pancreatic cancer on Tuesday, Nov. 17, 2009, in Room 202 of the Hynes Convention Center in Boston, Mass., from 1:00 p.m. to 2:00 p.m. ET.

18 Nov 2009

Updated efficacy results from Allos Therapeutics' FOLOTYN study to be presented at the ASH meeting

Allos Therapeutics, Inc. today announced that abstracts from studies of FOLOTYN™ (pralatrexate injection) were accepted for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) to be held at the Ernest N. Morial Convention Center in New Orleans, La., from December 5-8, 2009.

12 Nov 2009

FDA grants Abraxis BioScience orphan drug designation for ABRAXANE

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug designation to the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of pancreatic cancer as well as stage IIB-IV melanoma.

5 Nov 2009

ArQule reports financial results for the fiscal quarter and nine months ended September 30, 2009

ArQule, Inc. today reported its results of operations for the fiscal quarter and nine months ended September 30, 2009.

5 Nov 2009

Seattle Genetics reports its third-quarter financial results

Seattle Genetics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. The company also highlighted recent product development progress.

24 Oct 2009

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

Seattle Genetics, Inc. announced today that it has discontinued the SeaGen MARINER clinical trial based on a determination that the trial would be unlikely to meet its primary endpoint of superior complete response rate in the dacetuzumab combination arm as compared to the placebo combination arm.

5 Oct 2009

Huachansu may slow cancer progression

Huachansu, a Chinese medicine that comes from the dried venom secreted by the skin glands of toads, has tolerable toxicity levels, even at doses eight times those normally administered, and may slow disease progression in some cancer patients, say researchers from The University of Texas M. D. Anderson Cancer Center.

25 Sep 2009

New method found for the treatment of pancreatic cancer

For the first time researchers have shown that by inhibiting the action of an enzyme called TAK-1, it is possible to make pancreatic cancer cells sensitive to chemotherapy, opening the way for the development of a new drug to treat the disease.

24 Sep 2009

Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trial showing that Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, significantly extended progression-free survival in patients with advanced breast cancer.

23 Sep 2009

Rexahn and Teva sign license and stock purchase agreements

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it has closed on its previously announced licensing and stock purchase agreements with Teva Pharmaceutical Industries Limited, a top 20 pharmaceutical company, for the development of its novel anti-cancer compound, RX-3117. RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that has an anti-metabolite mechanism of action, and has therapeutic potential in a broad range of cancers including colon, lung and pancreatic cancer.

22 Sep 2009

Pfizer Oncology to present early-stage research of investigational agents for cancer treatment

Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer, updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET), and early-stage research of investigational agents PF-02341066 and figitumumab (CP-751,871) in patients with non-small cell lung cancer (NSCLC).

19 Sep 2009

Pharmacyclics announces financial results for fourth quarter and FY 2009

Pharmacyclics, Inc. today reported financial results for its fourth quarter and fiscal year ended June 30, 2009. During the fourth quarter of fiscal 2009 Pharmacyclics incurred a GAAP net loss of $5.4 million, or $0.20 per share, compared to a net loss of $4.6 million, or $0.18 per share for the fourth quarter of fiscal 2008.

18 Sep 2009

Notice of Allowance issued by PTO for OSI's EGFR drug

OSI Pharmaceuticals, Inc. announced today that the U.S. Patent & Trademark Office has issued a “Notice of Allowance” in OSI’s reissue application for U.S. Patent No.5,747,498 (the ‘498) composition of matter patent for Tarceva® (erlotinib). The reissued patent will replace the original ‘498 patent and have the same November 2018 expiration date.

18 Sep 2009

Rexahn to sign licensing and stock purchase agreements with Teva Pharmaceutical

18 Sep 2009

Sanofi-aventis and Regeneron Pharmaceuticals discontinue Phase 3 trial of aflibercept

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. today announced the discontinuation of the Phase 3 trial that evaluated aflibercept (VEGF Trap) plus gemcitabine versus placebo plus gemcitabine for the first-line treatment of metastatic pancreatic cancer (VANILLA), based on the recommendations by an Independent Data Monitoring Committee (IDMC).

14 Sep 2009

Gemcitabine News and Research

Positive clinical data from Phase II study of elacytarabine in patients with AML reported

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

Data from brentuximab vedotin and dacetuzumab programs to be presented by Seattle Genetics

Cromoz's new drug delivery system to reduce amount of drugs used in cancer treatment

Clavis Pharma signs drug development and commercialisation agreement with Clovis Oncology

Press conference highlights emerging treatments in pancreatic cancer

Updated efficacy results from Allos Therapeutics' FOLOTYN study to be presented at the ASH meeting

FDA grants Abraxis BioScience orphan drug designation for ABRAXANE

ArQule reports financial results for the fiscal quarter and nine months ended September 30, 2009

Seattle Genetics reports its third-quarter financial results

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

Huachansu may slow cancer progression

New method found for the treatment of pancreatic cancer

Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced

Rexahn and Teva sign license and stock purchase agreements

Pfizer Oncology to present early-stage research of investigational agents for cancer treatment

Pharmacyclics announces financial results for fourth quarter and FY 2009

Notice of Allowance issued by PTO for OSI's EGFR drug

Rexahn to sign licensing and stock purchase agreements with Teva Pharmaceutical

Sanofi-aventis and Regeneron Pharmaceuticals discontinue Phase 3 trial of aflibercept

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News